Virginia Retirement Systems ET AL boosted its position in Celgene Co. (NASDAQ:CELG) by 39.6% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 458,500 shares of the biopharmaceutical company’s stock after purchasing an additional 130,000 shares during the quarter. Virginia Retirement Systems ET AL owned about 0.07% of Celgene worth $41,031,000 at the end of the most recent quarter.
Other large investors have also recently modified their holdings of the company. Prospera Financial Services Inc bought a new stake in Celgene in the 2nd quarter valued at about $352,000. Bangor Savings Bank increased its stake in Celgene by 21.2% during the 3rd quarter. Bangor Savings Bank now owns 18,049 shares of the biopharmaceutical company’s stock valued at $1,615,000 after buying an additional 3,157 shares during the period. Korea Investment CORP increased its stake in Celgene by 1.5% during the 2nd quarter. Korea Investment CORP now owns 674,446 shares of the biopharmaceutical company’s stock valued at $53,565,000 after buying an additional 10,000 shares during the period. Headinvest LLC acquired a new position in Celgene during the 2nd quarter valued at about $1,819,000. Finally, NumerixS Investment Technologies Inc acquired a new position in Celgene during the 2nd quarter valued at about $1,548,000. Hedge funds and other institutional investors own 73.58% of the company’s stock.
Shares of Celgene stock traded up $0.20 during trading on Wednesday, hitting $75.29. The stock had a trading volume of 489,009 shares, compared to its average volume of 5,961,691. The company has a market cap of $51.88 billion, a P/E ratio of 11.01, a price-to-earnings-growth ratio of 0.46 and a beta of 1.53. The company has a debt-to-equity ratio of 4.06, a current ratio of 2.13 and a quick ratio of 1.99. Celgene Co. has a 1 year low of $70.09 and a 1 year high of $110.81.
CELG has been the topic of several research analyst reports. Zacks Investment Research cut shares of Celgene from a “buy” rating to a “hold” rating in a research note on Wednesday, September 26th. Mizuho set a $117.00 target price on shares of Celgene and gave the company a “buy” rating in a research note on Tuesday, October 30th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Celgene in a research note on Thursday, October 11th. Cantor Fitzgerald initiated coverage on shares of Celgene in a research note on Monday, October 1st. They set an “overweight” rating and a $100.00 target price on the stock. Finally, BidaskClub cut shares of Celgene from a “buy” rating to a “hold” rating in a research note on Thursday, September 13th. Three research analysts have rated the stock with a sell rating, eleven have issued a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $117.91.
In other news, Director Ernest Mario sold 12,000 shares of Celgene stock in a transaction that occurred on Thursday, August 9th. The shares were sold at an average price of $92.32, for a total value of $1,107,840.00. Following the transaction, the director now directly owns 44,413 shares of the company’s stock, valued at $4,100,208.16. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.39% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was first published by Week Herald and is owned by of Week Herald. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://weekherald.com/2018/11/07/virginia-retirement-systems-et-al-purchases-130000-shares-of-celgene-co-celg.html.
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Featured Article: Compound Annual Growth Rate (CAGR)
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.